519006-12-3

Upstream product

• 98-74-8 4-Nitrobenzenesulfonyl chloride 
• 67-64-1 acetone 
• 403825-44-5 1‐(4‐nitrophenylsulfonyl)piperazine 
• 173951-83-2 N-((4-nitrophenyl)sulfonyl)-1-(tert-butyloxycarbonyl)piperazine 
• 4318-42-7 1-(1-methylethyl)piperazine 

Downstream Products

• 524719-43-5 4-((4-isopropylpiperazin-1-yl)sulfonyl)aniline 

Relevant academic research and scientific papers

Identification of N-phenyl-3-methoxy-4-pyridinones as orally bioavailable H3 receptor antagonists and β-amyloid aggregation inhibitors for the treatment of Alzheimer's disease

Based on our previous work, a series of N-phenyl-3-methoxy-4-pyridinone derivatives were designed as orally bioavailable dual functional agents for therapy of Alzheimer's disease, through introducing alkyloxy moiety into 4-pyridinone ring to avoid the pos

Exploration of secondary and tertiary pharmacophores in unsymmetrical N,N′-diaryl urea inhibitors of soluble epoxide hydrolase

The impact of various secondary and tertiary pharmacophores on in vitro potency of soluble epoxide hydrolase (sEH) inhibitors based on the unsymmetrical urea scaffold 1 is discussed. N,N′-Diaryl urea inhibitors of soluble epoxide hydrolase exhibit subtle variations in inhibitory potency depending on the secondary pharmacophore but tolerate considerable structural variation in the second linker/tertiary pharmacophore fragment.

SOLUBLE EPOXIDE HYDROLASE INHIBITORS

Disclosed are sulfonamide compounds and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, pulmonary, and diabetes-related diseases.